Evaluation of double immunocytochemical staining for CK20 and P53 as a potential adjunct to cytology for urothelial cancer diagnosis

Urinary immunocytology—Promise or nonseller? A review with an opinion

(2014) Malte Böhm et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

Utility of a Triple Antibody Cocktail Intraurothelial Neoplasm-3 (IUN-3-CK20/CD44s/p53) and α-Methylacyl-CoA Racemase (AMACR) in the Distinction of Urothelial Carcinoma In Situ (CIS) and Reactive Urothelial Atypia

(2013) Manju Aron et al.   AMERICAN JOURNAL OF SURGICAL PATHOLOGY

EAU Guidelines on Non–Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2013

(2013) Marko Babjuk et al.   EUROPEAN UROLOGY

Bladder Cancer Detection and Monitoring: Assessment of Urine- and Blood-Based Marker Tests

(2013) Steve Goodison et al.   Molecular Diagnosis & Therapy

Epidemiology and Risk Factors of Urothelial Bladder Cancer

(2012) Maximilian Burger et al.   EUROPEAN UROLOGY

Combination of CK20 and Ki-67 Immunostaining Analysis Predicts Recurrence, Progression, and Cancer-Specific Survival in pT1 Urothelial Bladder Cancer

(2012) Simone Bertz et al.   EUROPEAN UROLOGY

Immunocytology Is a Strong Predictor of Bladder Cancer Presence in Patients With Painless Hematuria: A Multicentre Study

(2011) Eugene K. Cha et al.   EUROPEAN UROLOGY

Accuracy of Urine Cytology and the Significance of an Atypical Category

(2009) Fadi Brimo et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Which urine marker test provides more diagnostic value in conjunction with standard cytology- ImmunoCyt/uCyt+ or Cytokeratin 20 expression

(2009) Isin Soyuer et al.   Diagnostic Pathology

Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies

(2009) Isil Z Yildiz et al.   Diagnostic Pathology